These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20382019)

  • 41. Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists.
    Duan JJ; Jiang B; Lu Z; Stachura S; Weigelt CA; Sack JS; Khan J; Ruzanov M; Wu DR; Yarde M; Shen DR; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
    Bioorg Med Chem Lett; 2020 Oct; 30(19):127441. PubMed ID: 32736080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold.
    Goher SS; Griffett K; Hegazy L; Elagawany M; Arief MMH; Avdagic A; Banerjee S; Burris TP; Elgendy B
    Bioorg Med Chem Lett; 2019 Feb; 29(3):449-453. PubMed ID: 30587446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of new liver X receptor agonists by pharmacophore modeling and shape-based virtual screening.
    Temml V; Voss CV; Dirsch VM; Schuster D
    J Chem Inf Model; 2014 Feb; 54(2):367-71. PubMed ID: 24502802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and In Vitro Evaluation of Novel Liver X Receptor Agonists Based on Naphthoquinone Derivatives.
    Nishioka T; Endo-Umeda K; Ito Y; Shimoda A; Takeuchi A; Tode C; Hirota Y; Osakabe N; Makishima M; Suhara Y
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 6-Substituted quinolines as RORγt inverse agonists.
    Barbay JK; Cummings MD; Abad M; Castro G; Kreutter KD; Kummer DA; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Tanis VM; Urbanski M; Venkatesan H; Wang A; Woods C; Wolin R; Xue X; Edwards JP; Fourie AM; Leonard K
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5277-5283. PubMed ID: 29079472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of Highly Potent Liver X Receptor β Agonists.
    Kick EK; Busch BB; Martin R; Stevens WC; Bollu V; Xie Y; Boren BC; Nyman MC; Nanao MH; Nguyen L; Plonowski A; Schulman IG; Yan G; Zhang H; Hou X; Valente MN; Narayanan R; Behnia K; Rodrigues AD; Brock B; Smalley J; Cantor GH; Lupisella J; Sleph P; Grimm D; Ostrowski J; Wexler RR; Kirchgessner T; Mohan R
    ACS Med Chem Lett; 2016 Dec; 7(12):1207-1212. PubMed ID: 27994765
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.
    Narjes F; Llinas A; von Berg S; Jirholt J; Lever S; Pehrson R; Collins M; Malmberg A; Svanberg P; Xue Y; Olsson RI; Malmberg J; Hughes G; Hossain N; Grindebacke H; Leffler A; Krutrök N; Bäck E; Ramnegård M; Lepistö M; Thunberg L; Aagaard A; McPheat J; Hansson EL; Chen R; Xiong Y; Hansson TG
    J Med Chem; 2021 Sep; 64(18):13807-13829. PubMed ID: 34464130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of novel silanol-based human pregnane X receptor (PXR) agonists with improved receptor selectivity.
    Toyama H; Shirakawa H; Komai M; Hashimoto Y; Fujii S
    Bioorg Med Chem; 2018 Aug; 26(15):4493-4501. PubMed ID: 30077610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches.
    Chen M; Yang F; Kang J; Gan H; Yang X; Lai X; Gao Y
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29867043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical Properties of TAK-828F, a Potent and Selective Retinoid-Related Orphan Receptor Gamma t Inverse Agonist.
    Nakagawa H; Koyama R; Kamada Y; Ochida A; Kono M; Shirai J; Yamamoto S; Ambrus-Aikelin G; Sang BC; Nakayama M
    Pharmacology; 2018; 102(5-6):244-252. PubMed ID: 30134246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of a 2-hydroxyacetophenone derivative as an outstanding linker to enhance potency and β-selectivity of liver X receptor agonist.
    Koura M; Yamaguchi Y; Kurobuchi S; Sumida H; Watanabe Y; Enomoto T; Matsuda T; Okuda A; Koshizawa T; Matsumoto Y; Shibuya K
    Bioorg Med Chem; 2016 Aug; 24(16):3436-46. PubMed ID: 27283790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis of riccardin C and its seven analogues. Part 1: The role of their phenolic hydroxy groups as LXRalpha agonists.
    Hioki H; Shima N; Kawaguchi K; Harada K; Kubo M; Esumi T; Nishimaki-Mogami T; Sawada J; Hashimoto T; Asakawa Y; Fukuyama Y
    Bioorg Med Chem Lett; 2009 Feb; 19(3):738-41. PubMed ID: 19103488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural development of tetrachlorophthalimides as liver X receptor β (LXRβ)-selective agonists with improved aqueous solubility.
    Nomura S; Endo-Umeda K; Fujii S; Makishima M; Hashimoto Y; Ishikawa M
    Bioorg Med Chem Lett; 2018 Feb; 28(4):796-801. PubMed ID: 29398545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Casting a shadow on liver X receptor-mediated atheroprotection: is LXRβ to blame?
    Degirolamo C; Moschetta A
    J Intern Med; 2012 Nov; 272(5):449-51. PubMed ID: 22651910
    [No Abstract]   [Full Text] [Related]  

  • 55. Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalization.
    Shi Q; Xiao Z; Yang MG; Marcoux D; Cherney RJ; Yip S; Li P; Wu DR; Weigelt CA; Sack J; Khan J; Ruzanov M; Wang J; Yarde M; Ellen Cvijic M; Li S; Shuster DJ; Xie J; Sherry T; Obermeier M; Fura A; Stefanski K; Cornelius G; Chacko S; Shu YZ; Khandelwal P; Hynes J; Tino JA; Salter-Cid L; Denton R; Zhao Q; Dhar TGM
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127521. PubMed ID: 32882417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design of a Potent TLX Agonist by Rational Fragment Fusion.
    Faudone G; Zhubi R; Celik F; Knapp S; Chaikuad A; Heering J; Merk D
    J Med Chem; 2022 Feb; 65(3):2288-2296. PubMed ID: 34989568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis of Quinoline Silyloxymethylsulfones as Intermediates to Sulfonyl Derivatives.
    Patel TI; Laha R; Moschitto MJ
    J Org Chem; 2022 Nov; 87(22):15679-15683. PubMed ID: 36305839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Molecular modeling of interaction of 17(20)Z- and 17(20)E-pregna-5,17(20)-dien-21-oyl amides with the nuclear receptor LXRbeta].
    Fediushkina IV; Stulov SV; Dugin NO; Misharin AIu; Mekhtiev AR; Morozevich GE; Veselovskiĭ AV
    Biomed Khim; 2013; 59(3):321-9. PubMed ID: 23987069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists.
    Duan JJ; Lu Z; Jiang B; Stachura S; Weigelt CA; Sack JS; Khan J; Ruzanov M; Galella MA; Wu DR; Yarde M; Shen DR; Shuster DJ; Borowski V; Xie JH; Zhang L; Vanteru S; Gupta AK; Mathur A; Zhao Q; Foster W; Salter-Cid LM; Carter PH; Dhar TGM
    ACS Med Chem Lett; 2019 Mar; 10(3):367-373. PubMed ID: 30891142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What's new in shock, November 2009?
    Clemens MG
    Shock; 2009 Nov; 32(5):461-2. PubMed ID: 19829239
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.